About Apremilast (Amorphous & Form B) API
Therapeutic CategoryCentral Nervous System (CNS)
CAS Number
608141-41-9
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, Canada DMF
Mechanism of Action
Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.
Indication
OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
- Adult patients with active psoriatic arthritis
- Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Related APIs
Eslicarbazepine Acetate
Central Nervous System (CNS)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
Dr.Reddy's Apremilast API and finished formulation offerings.
Dr. Reddy's is one of the leading API pharma companies supplying Apremilast API globally, and has led the USDMF filing in September 2016 (Form-B) and June 2017 (Amorphous).Apremilast, is an anti-inflammatory agent modulating a wide range of inflammatory mediators in psoriasis and psoriatic arthritis. Apremilast is indicated for the treatment of active psoriatic arthritis and moderate to severe plaque psoriasis.Dr. Reddy's amorphous API has been successfully formulated into drug products by various formulators with successful bioequivalence studies and subsequent dossier filing.To know more about our offerings , please read the technical sheet on Apremilast by filling the contact from below.
